

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

Claims 20, 33 and 47 were pending in this application when last examined.

Claim 20 was indicated as allowed. Further, claim 47 was objected to but was indicated as allowable if rewritten in independent form. Claim 33 was rejected.

Claim 33 is amended to include the limitation of claim 47. Claim 47 has further been cancelled as duplicative. No new matter has been added.

On pages 2-3 of the Office Action, claim 33 was rejected under 35 U.S.C. §112 first paragraph, because the specification, while being enabling for a percutaneous absorption preparation comprising (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8yl)ethyl]acetamide (A = furan; X = CH₂, Y = C) or (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8yl)ethyl]propionamide (A = furan; X = CH₂, Y = C), does not reasonably provide enablement for a percutaneous absorption preparation comprising compounds of instant formula disclosed in claim 33 other than (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8yl)ethyl]propionamide.

Applicants note that claim 33 has been amended to incorporate the limitations of claim 47. Such subject matter has been indicated as enabled by the Office. Thus, this rejection is overcome.

Claim 47 was also objected to on page 4 of the Office Action. This objection is moot.

CONCLUSION

In view of the foregoing amendments and remarks, it is respectfully submitted that the present application is in condition for allowance and early notice to that effect is hereby requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact the undersigned attorney at the telephone number below.

Respectfully submitted,

Yasuyuki SUZUKI et al.

By: 
William R. Schmidt, II
Registration No. 58,327
Attorney for Applicants

WRS/lc
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
September 16, 2008